Neuphoria Therapeutics Inc. (NEUP): Total Liabilities
$4.11M
As of 2026-06-30
-14.4%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $4.11M | -57.1% | 2026-09-18, Balance as of period end |
| 2025-06-30 | $9.59M | -5.6% | 2026-09-18, Balance as of period end |
| 2024-06-30 | $10.16M | +55.0% | 2025-09-29, Balance as of period end |
| 2023-06-30 | $6.55M | n/a | 2024-09-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $4.11M | -57.1% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $4.59M | +24.9% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $5.05M | -18.9% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $13.04M | -6.5% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $2.42M | -6.4% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $29.63M | +5.4% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $37.17M | +21.3% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $1.99M | +10.1% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $128.86M | +21.9% |
Compare NEUP, LGVN, SXTC, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗